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A B S T R A C T
Purpose
The aim of this study was to assess the management and the obstetrical and neonatal outcomes
of pregnancies complicated by cancer.
Patients and Methods
In an international collaborative setting, patients with invasive cancer diagnosed during pregnancy
between 1998 and 2008 were identified. Clinical data regarding the cancer diagnosis and
treatment and the obstetric and neonatal outcomes were collected and analyzed.
Results
Of 215 patients, five (2.3%) had a pregnancy that ended in a spontaneous miscarriage and 30
(14.0%) pregnancies were interrupted. Treatment was initiated during pregnancy in 122 (56.7%)
patients and postpartum in 58 (27.0%) patients. The most frequently encountered cancer types
were breast cancer (46%), hematologic malignancies (18%), and dermatologic malignancies
(10%). The mean gestational age at delivery was 36.3  2.9 weeks. Delivery was induced in
71.7% of pregnancies, and 54.2% of children were born preterm. In the group of patients
prenatally exposed to cytotoxic treatment, the prevalence of preterm labor was increased (11.8%;
P .012). Furthermore, in this group a higher proportion of small-for-gestational-age children (birth
weight below 10th percentile) was observed (24.2%; P  .001). Of all neonates, 51.2% were
admitted to a neonatal intensive care unit, mainly (85.2%) because of prematurity. There was no
increased incidence of congenital malformations.
Conclusion
Pregnant cancer patients should be treated in a multidisciplinary setting with access to maternal
and neonatal intensive care units. Prevention of iatrogenic prematurity appears to be an important
part of the treatment strategy.
J Clin Oncol 28:683-689. © 2009 by American Society of Clinical Oncology
INTRODUCTION
Cancer treatment during pregnancy is a challenge.
Although surgery has been shown to be safe dur-
ing pregnancy,1,2 only a few drugs have been
tested in pregnant women. Hence, most drugs are
classified as “contraindicatedduringpregnancy, un-
less strictly needed.”3 Therefore, physiciansmust as-
sesswhether thebenefitsof treatment for themother
outweigh the potential risk to the fetus.
Chemotherapy and radiotherapy were long
considered incompatiblewith normal fetal develop-
ment. This policy resulted in either termination of
pregnancy or suboptimal cancer treatment for the
mother. Clinicians have gained some experience in
this field from case reports and small studies. In
contrast to previous assumptions, the short-term
outcome after prenatal exposure to chemotherapy
or radiotherapy initiated after the first gestational
trimester appears to be positive.4-7 Studies on the
long-term outcome of prenatal exposure to chemo-
therapy show a reassuring outcome for the chil-
dren.8,9 However, because the described or applied
methodology in these studies was rather poor, addi-
tional research is necessary.
The concurrence of cancer and pregnancy is a
relatively rare problem, occurring in about one in
1,000 pregnancies.10 Therefore, single institutional
or regional initiatives will not be able to provide
sufficient information on the safety of cancer treat-
ment during pregnancy for both the mother and
fetus. Since more women are delaying childbearing
and the incidence of cancer in the 30 to 49 years age
group is increasing, it can be expected that in the
future, cancer will be diagnosedmore often in preg-
nant women.11,12 To gain more data and obtain
better counseling for the patient, the need for a
multicenter registration is growing.13 Therefore, we
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initiated an international collaborative study investigating the prob-
lem of cancer during pregnancy. In this study, we focus on manage-
ment options and the impact on the obstetric andneonatal outcomes.
PATIENTS AND METHODS
In an international collaborative setting, patients with invasive cancer diag-
nosed during pregnancy were identified. Patients with a preinvasive disease
were excluded. To ensure uniformity in obstetric and oncologic manage-
ment, patients diagnosed before 1998 were excluded in the current analy-
ses. The studywas approvedby the institutional reviewboard in theUniversity
Hospitals of Leuven, Belgium; Nijmegen, the Netherlands; and Prague,
Czech Republic.
Because information on pregnant state is not available in most cancer
registries and because oncologic problems are not registered in perinatal data
sets, we attempted to contact as many physicians who treat pregnant cancer
patients as possible by means of networking (eg, mailing members of the
Flemish Society of Obstetrics and Gynecology); newsletters; presentations at
congresses for obstetricians, hematologists, or oncologists; and a Web site
(www.cancerinpregnancy.org). We asked physicians to register the patients
they treat or had treated and to trace patients by means of their institutional
data sets and hospital registration systems.
In Belgium, a collaborationwas establishedwith the FoundationCancer
Registry and onemedical insurance organization (National Alliance of Chris-
tian Sickness Funds). Registration codes for chemotherapy and radiotherapy
were linked to the code for delivery or inuterodeath ( 16weeks of gestation)
with amaximum time interval of 9 months between both. The list of patients
we obtained was fine-tuned in such a way that only the patients with a cancer
diagnosis during pregnancy remained. Treating physicians of these patients
were contacted by the Foundation Cancer Registry with a request to register
their patients anonymously in this study.
Clinical data were collected and analyzed in accordance with local pri-
vacy legislation. Oncologic, obstetric, and pediatric files were screened to
retrieve clinical information. Oncologic data included the type of cancer, the
date of diagnosis, and the type and date of treatment. Obstetric data we
attempted to retrieve included gestational age at diagnosis, obstetric compli-
cations, gestational age at delivery, andmode of delivery (induction, cesarean
section, spontaneous labor). Pediatric data collected included birth weight,
sex, congenital malformations, admission to neonatal intensive care unit
(NICU), and reason for admission.
All data were collected in a Microsoft Access database and processed
in Microsoft Excel 2007 (Microsoft, Redmond, WA). Unless mentioned
otherwise, values are reported as mean standard deviation. Statistical test-
ing was performed with Graphpad Prism 5 and its online software (http://
www.graphpad.com/quickcalcs/index.cfm). Two-sided tests were applied.
TheWilcoxon rank sum test was used for comparing continuous variables in
two groups; formore than two groups, the Kruskal-Wallis exact test was used.
A binomial exact test was used for comparing a proportion with an expected
value. Results were considered significant at P .05.
RESULTS
Between1998and2008, 215patientswith adiagnosis of cancerduring
pregnancy were registered. The distribution by country was 147
(68.4%) in Belgium, 55 (25.6%) in theNetherlands, and 13 (6.0%) in
theCzechRepublic.Thematernal ageatdiagnosiswas33.24.8years
and the gestational age was 21.0 10.8 weeks. The timing of cancer
diagnosis in pregnancy was distributed as follows: 52 (24.2%) in the
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Fig 1. (A) Management of cancer during pregnancy per trimester (n  215). (B)
Distribution of birth weight (n  175) expressed in percentile for gestational age
(p) (*P  .012).
Table 1. Distribution of Tumor Types
Tumor Type No. %
Breast cancer 99 46
Hematologic malignancies 40 18
Hodgkin’s disease 13 6.0
Non-Hodgkin’s lymphoma 10 4.7
Acute lymphatic leukemia 4 1.9
Acute myelogenous leukemia 7 3.2
Chronic myelogenous leukemia 4 1.9
Hairy cell leukemia 1 0.5
Multiple myeloma 1 0.5
Dermatologic malignancies 21 10
Basal cell carcinoma 9 4.2
Melanoma 11 5.1
Kaposi’s sarcoma 1 0.5
Cervical cancer 17 8
Brain tumor 8 4
Ovarian cancer 8 4
Colorectal cancer 5 2
Other (sarcoma, lung, liver, kidney, GI stromal tumor,
thyroid, urachus, rhinopharyngeal) 17 8
Total 215 100
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first trimester, 92 (42.8%) in the second trimester, and 71 (33.0%) in
the third trimester.
Oncologic Problems
The distribution of cancer types is depicted in Table 1. Themost
frequently encountered tumor typeswere breast cancer (46%), hema-
tologic malignancies (18%), and dermatologic malignancies (10%).
Primary and recurrent cancer were diagnosed in 204 and 11 pa-
tients, respectively.
Treatment Policy Related to Pregnancy
In five (2.3%) of 215 patients, a miscarriage occurred at 10.7
4.8 weeks of gestation, before cancer treatment was started. In 30
(14.0%)of 215patients, the pregnancywas terminated at a gestational
age of 10.9 6.8 weeks. In 13 patients (43.3%), pregnancy termina-
tion occurred after a gestational age of 13 weeks. In 29 of 30 patients,
maternal cancer was the reason for termination. In only one patient,
thepregnancywasunwanted. In58 (27.0%)of215patients, treatment
was delayed until postpartum.Here, the cancer diagnosis wasmade at
a gestational age of 30.6 9.4weeks. In 122 (56.7%) of 215 patients, a
single or a combination of treatment modalities was initiated during
pregnancy after a cancer diagnosis at a gestational age of 19.6  8.5
weeks. The distribution of therapies used during pregnancy was as
follows: 40.2% surgery (n  49), 27.0% chemotherapy (n  33),
20.5% surgery and chemotherapy (n  25), 2.6% radiotherapy
(n 3), 2.5% surgery and radiotherapy (n 3), 2.5% surgery, chem-
otherapy, and radiotherapy (n  3), 1.6% interferon (n  2), 0.8%
chemotherapy and radiotherapy (n 1), 0.8% cryotherapy (n 1),
0.8% hormonal therapy (n  1), and 0.8% monoclonal antibody
(n  1). A total of 62 women received chemotherapy and 10
received radiotherapy (AppendixTableA1, online only). Theman-
agement per gestational trimester is shown is Figure 1A.
Obstetric Outcomes
For the processing of obstetric data, miscarriages (n  5) and
abortions (n 30)were excluded, leaving 180 pregnancies for further
analysis. In 27 (15%) of 180 patients, a gestational complication was
registered.Thedistributionper treatmentgroup isdepicted inTable2.
When compared with preterm premature rupture of membranes
(PPROM) and preterm labor incidences in the normal population
(PPROM, 3%; spontaneous preterm labor, 4%),14 no increase was
seen (PPROM, three [1.7%] of 180; P not significant, and preterm
labor, eight [4.4%] of 180; P  .864 [binomial test]). However, a
subanalysis for the patients exposed to chemotherapy and/or radio-
therapy revealed a significant increase in preterm labor (eight [11.8%]
of 68; P .012 [binomial test]), but not of PPROM (three [4.4%] of
68; P  .668 [binomial test]). These findings were even more pro-
nounced looking only at chemotherapy-exposed pregnancies (pre-
term labor, eight [12.9%] of 62; P .006, and PPROM, three [4.8%]
of 62; P .568 [binomial test]).
Table 3 shows the distribution of the different types of labor and
the gestational age at delivery related to the oncologic treatment.
Induction of labor or an elective cesarean section was performed in
71.7%(n129)of thepregnancies at ameangestational ageof35.6
2.8 weeks. Maternal cancer was the indication for induction/cesarean
section in 76.7% of these pregnancies (oncologic reasons, n  99;
obstetric reasons, n 21; unknown, n 9).
Table 2. Obstetric Complications According to Treatment Modality (n  180)
Treatment Group No. % Complications
Gestational Age at Diagnosis
(weeks; days after treatment)
No treatment (n  58) 6 10.3 PIH (n  2) 35.4, NA
Preeclampsia (n  1) NA
Gestational cholestasis (n  1) 33.5
Preterm contractions (n  1) 36.0
Antepartum bleeding (n  1) 23.4
Chemotherapy (n  33) 13 39.4 Gestational diabetes (n  1) 29.6
Preterm contractions (n  2) 31.0 (0), 31.5 (0)
PPROM (n  3) 28.0 (10), 32.5 (35), 34.4 (10)
Sepsis (n  1) 26.2 (0)
Preterm labor (n  6) 28.0 (11), 32.2 (2), 33.1 (11), 34.4 (8), 36.0
(20), 36.5 (21)
Chemotherapy  surgery (n  25) 4 16.0 Preterm contractions (n  1) 27.0 (0 after surgery)
Sepsis (n  1) 26.0 (1 after chemotherapy)
Preterm labor (n  2) 34.0, 34.3 (34 and 59 after chemotherapy)
Surgery (n  49) 3 6.1 IUGR (n  1) NA
Preterm contractions (n  1) 30 (NR)
Sepsis (n  1) 35.3 (NR)
Radiotherapy (n  3) 1 33.3 IUGR (n  1) 28 (10)
Chemotherapy  radiotherapy (n  1) 0 0.0
Radiotherapy  surgery (n  3) 0 0.0
Surgery  chemotherapy  radiotherapy (n  3) 0 0.0
Others (n  5) 0 0.0
Total 27 15.0
Abbreviations: PIH, pregnancy induced hypertension; NA, not available; PPROM, preterm premature rupture of membranes; IUGR, intrauterine growth restriction;
NR, not related.
Preterm contractions: contractions without cervical changes.
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Neonatal Outcome
Data on the gestational age at delivery were available for 179 of
the 185 children—180 pregnancies, with three twins and one triplet.
The mean gestational age at delivery was 36.2 2.9 weeks. Delivery
occurred for 15 (8.4%) of 179 children before 32 weeks of gestation,
for 82 (45.8%) of 179 children between 32 and 37 weeks of gestation,
and for 82 (45.8%) of 179 children at term ( 37 weeks). For the 97
preterm children, labor started spontaneously in eight pregnancies
(8.2%), and induction of labor/cesarean section was performed in 87
(89.7%) with two unknown (2.1%). The indication for induction of
labor/cesarean section was maternal cancer for 88%, whereas there
were obstetric indications for delivering the baby preterm in 12%.
Data on the birth weight of 175 children were available (166
children from singleton pregnancies, six children from three twin
pregnancies, and three children from one triplet pregnancy). In 26 of
175 children, the birth weight was below the 10th percentile for gesta-
tional age (14.9%; P  .054 [binomial test]). A subanalysis of this
group (Table 4) shows a large proportion of small-for-gestational-age
children (birth weight below 10th percentile) and children who have
hematologic tumors (nine [27.3%] of 33).
Binomial testing revealed a significant increase in small-for-
gestational-age children in the group receiving treatmentduringpreg-
nancy (n  21 [17.9%] of 117; P  .012) versus not treated in
pregnancy (n 5 [8.6%] of 58; P not significant). The distribution
of the birth weight expressed by percentile for gestational age in the
group with and without treatment during pregnancy is presented in
Figure 1B. Looking specifically at cytotoxic treatment (chemotherapy
and/or radiotherapy), small-for-gestational-agebabieswere seen in16
(24.2%)of 66pregnancies (P .001 [binomial test]) versus 10 (9.2%)
of 109 in pregnancies without cytotoxic treatment (P not signif-
icant [binomial test]).
Thepatients in the chemotherapy groupwhohad childrenwith a
birth weight below the 10th percentile were treated for acute myelog-
enous leukemia (n  3), acute lymphatic leukemia (n  1), breast
cancer (n 3), Hodgkin’s disease (n 2), and non-Hodgkin’s lym-
phoma(n1); thepatients receiving chemotherapyand surgerywere
treated for ovarian cancer (n 2), breast cancer (n 1), and colon
carcinoma (n  1). Small-for-gestational-age children of the two
patients exposed toradiotherapywere treated fornon-Hodgkin’s lym-
phoma and sarcoma.
Data on the outcome of 175 neonates were available for analysis.
Aphysical abnormalitywasdiagnosed in13childrenatbirth(Table5).
Comparedwith the background risk ofmajormalformations of 4.1%
to 6.9% and risk of minor malformations of 6.5% to 35.8%,15-17
these data do not show an increased incidence of physical malfor-
mations at birth. Major and minor malformations were observed in
Table 3. Labor Modalities
Labor
All Pregnancies No Treatment During Pregnancy Treatment During Pregnancy
No. of
Pregnancies %
Gestational Age
(mean No. of
weeks  SD)
No. of
Pregnancies %
Gestational Age
(mean No. of
weeks  SD)
No. of
Pregnancies %
Gestational Age
(mean No. of
weeks  SD)
Spontaneous 41 22.8 38.3  2.4 12 20.7 39.3  1.1 29 23.8 37.8  2.7
Induction 66 36.7 36.5  2.3 18 31.0 37.0  2.8 48 39.3 36.4  2.1
Elective cesarean section 63 35.0 34.7  2.9 25 43.1 35.1  3.1 38 31.1 34.4  2.8
Unknown 10 5.6 — 3 5.2 — 7 5.7 —
Total 180 36.3  2.9 58 36.7  3.1 122 36.1  2.8
Abbreviation: SD, standard deviation.
Table 4. Subanalysis of the Group With Birth Weight Below the 10th Percentile for Gestational Age
Birth Weight Below 10th Percentile
Tumor Type No. Total No. % Treatment During Pregnancy No. Total No. %
Acute lymphatic leukemia 1 3 33.3 Chemotherapy 10 33 30.3
Acute myelogenous leukemia 4 5 80.0 Surgery  chemotherapy 4 25 16.0
Hodgkin’s disease 2 11 18.2 Surgery  radiotherapy 1 2 50
Non-Hodgkin’s disease 2 9 22.2 Surgery 5 46 10.9
Chronic myelogenous leukemia 0 4 0.0 Radiotherapy 1 2 50.0
Hairy cell leukemia 0 1 0.0 No treatment 5 58 8.6
Breast cancer 6 82 7.3 Chemotherapy  radiotherapy 0 1 0
Cervical cancer 2 15 13.3 Chemotherapy  radiotherapy  surgery 0 3 0
GI cancer 2 4 50.0 Other treatments 0 5 0
Brain tumor 2 9 22.2
Ovarian cancer 2 8 25.0
Skin tumor 2 16 12.5
Sarcoma 1 3 33.3
Other (lung, renal, rhinopharyngeal, thyroid) 0 5 0.0
Total 26 175 14.9 26 175 14.9
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five (2.9%) of 175 and eight (4.6%) of 175 neonates, respectively. For
the subgroup of patients prenatally exposed to radiotherapy and/or
chemotherapy, incidences of malformations were within the normal
ranges (major: two [3.0%] of 66 andminor: five [7.5%] of 66).
Two children born 10 days after the administration of chem-
otherapy for maternal acute lymphatic leukemia (cytarabine 
mitoxantrone intrathecal methotrexate and prednisonemeth-
otrexate  vincristine  daunomycin  cyclophosphamide 
L-asparaginase  mercaptopurine), suffered from hematologic to-
xicity (leukopenia and pancytopenia) and needed hematologic
growth factors.
Information on admission to an NICU was available for 172
children. Eighty-eight (51.2%) children were hospitalized in the
NICU, and prematurity was the indication for admission in 75
(85.2%) of 88 children. Furthermore, three children (3.4%) were
hospitalized because of a congenital anomaly, three (3.4%) because of
dysmaturity, one (1.1%) because of respiratory insufficiency, and six
(6.8%) for observation.
One instance of intrauterine death was reported in a woman
suffering fromdiabeteswhose pregnancywas complicatedwith gesta-
tional hypertension. The patient refused a follow-up at a maternal
intensive care unit. At 39weeks, she consulted a gynecologist with loss
of fetal movements and an intrauterine death was diagnosed. During
the delivery, amasswas palpatedposterior to the vaginawhichproved
to be a newly diagnosed metastasized colon carcinoma. It is unlikely
that this fetal loss was directly attributed to the cancer.
DISCUSSION
In this observational study, we report on a large series of patients with
cancer diagnosed during pregnancy. The most remarkable finding is
the observation that 54.2% of children were born preterm, with a
subsequently high rate of admission to theNICU. In the vastmajority
(89.7%), thedeliverywas iatrogenically induced.Thecomplicationsof
preterm birth are well studied and include intraventricular hemor-
rhage, bradycardia/apnea, need for respiratory assistance, necrotizing
Table 5. Physical Abnormalities Diagnosed at Birth Related to the Treatment Modality (n  175)
Treatment During
Pregnancy
Gestational Age at
Treatment (weeks) Treatment Modality Malformation
No. of
Children
With
Malformation
Total
No. of
Children %
None Prader-Willi 3 58 5.2
Congenital laryngomalacia
Hemangioma
Surgery 18 Partial nephrectomy  para-aortic
lymphadenectomy
Cardial hematomas in tuberous sclerosis
(autosomal dominant genetic disease)
3 46 6.5
32 Mastectomy Multiple congenital anomalies
(hypospadias, agenesis of left little
finger, abnormal position of left foot)
29 Lumpectomy  ALND Hemangioma
Chemotherapy 26, 29, 32 AC (3) Hip subluxation 3 33 9.1
25, 29, 33 MOPP/ABV (3) Pectus excavatum
24, 28, 32 HOVON70 Hemangioma
Chemotherapy 
radiotherapy RT: 15-19 Mantle field 40 Gy Bilateral partial syndactyly digiti II-III 1 1 100
CT: 26, 30 MOPP/ABV (2)
Surgery  chemotherapy S: 15 Lumpectomy Bilateral small protuberance on phalanx 5 2 25 8.0
S: 17 Mastectomy  ALND
CT: 20, 23, 26, 29, 32, 35 FEC (6)
S: 17 Lumpectomy  ALND Rectal atresia
CT: 23, 26, 29, 32 Epirubicin (4)
Surgery  chemotherapy 
radiotherapy S: 7 Lumpectomy  SND Doubled cartilage ring in both ears 1 3 33.3
S: 9 ALND
RT: 11-21 Thorax 50Gy  boost 16Gy
CT: 22, 25, 28 FAC (3)
Radiotherapy 0 2 0
Surgery  radiotherapy 0 2 0
Other (hormonal, interferon,
monoclonal antibody) 0 5 0
NOTE: Bold: major malformations as described by Merks et al.17
Abbreviations: ALND, axillary lymph node dissection; AC, doxorubicin 60 mg/m², cyclophosphamide 600 mg/m²; MOPP/ABV, mechlorethamine 6 mg/m², vincristine
1.4 mg/m², procarbazine 100 mg/m², prednisone 40 mg/m², doxorubicin 25 mg/m², vinblastine 6 mg/m², bleomycin 10 U/m²; HOVON70, prednisone 60 mg/m² orally
(PO; days 1-7), 40 mg/m2 PO (days 8-35), 40 mg/m² (days 8-28), methotrexate 15 mg intrathecally (days 1, 8, 15, 29, 43), vincristine 1.5 mg/m² intravenously (IV;
days 8, 15, 22, 29, 43); daunomycin 40 mg/m² IV (days 8, 15, 22); cyclophosphamide 1,000 mg/m² IV (day 8), L-asparaginase 6,000 U/m² IV (days 8, 10, 12, 15, 17,
19, 22, 24, 26), mercaptopurine 50 mg/m2 (days 29-49), methotrexate 5,000 mg/m2 IV (days 29, 43), methotrexate 25 mg/m2 PO (day 36), granulocyte
colony-stimulating factor (G-CSF) 150 g/m² (from day absolute neutrophil count ANC  0.5  109/L until ANC  1.0  109/L or day 43); RT, radiotherapy; CT,
chemotherapy; S, surgery; FEC, fluorouracil 500 mg/m², epirubicin 100 mg/m², cyclophosphamide 500 mg/m²; SND, sentinel node dissection; FAC, fluorouracil 500
mg/m², doxorubicin 60 mg/m², cyclophosphamide 500 mg/m².
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enterocolitis, sepsis, seizures, hypoglycemia, and feeding problems.
Recently Bastek et al18 showed that late-preterm neonates (34 to 37
weeks) have significantlymoremedical complications comparedwith
their full-term counterparts. In addition to these immediate effects,
preterm birth is also associated with long-term morbidities and im-
paired cognitive and behavioral outcomes.19 In this study, neonatal
problems were mainly due to iatrogenic, and therefore preventable,
prematurity. Prematurity canbepreventedbypostponingor continu-
ing treatment until a term delivery can be obtained.
Deliberatedelayof therapy to achieve fetalmaturity appears tobe
a safe option for patients with early-stage disease. For early-stage
breast cancer, Cold et al20 described the outcomes of a series of 7,501
patients and concluded that there was no evidence for a survival
benefit due to early initiation of adjuvant chemotherapy within the
first 2 to 3 months after surgery. Nettleton et al21 presented a mathe-
matical model to quantify the risk of axillary nodal metastases as a
result of delayed treatment of breast cancer during pregnancy. They
calculated that the daily increased risk of axillarymetastases as a result
of treatmentdelay is0.028%for tumorswithmoderatedoubling times
of 130 days and 0.057% for tumors with rapid doubling times of 65
days. They concluded that this minimal maternal risk may be ac-
ceptable to some third-trimester pregnantwomenwith early breast
cancer.21 Duggan et al22 described planned delay in patients with
stage IA and IB cervical cancer with a mean diagnosis-to-treatment
interval of 144days (range, 53 to 212days). All these patientswere free
of disease after a median follow-up of 23months.
Continuation of treatment started during pregnancy is a second
way to prevent prematurity. To date, treatment during pregnancy is
continueduntil fetal viability is reached. Instead, fetalmaturity should
preferably be the criterion to induce delivery. In a multidisciplinary
setting, amaximal effort should bemade todelay delivery until at least
35 to 37 weeks.
Malformations that were reported in this study are also seen in
a normal population. Furthermore, the incidence was not in-
creased. These observations confirm the notion that cytotoxic treat-
ment administered after the first trimester of pregnancy, the period of
embryogenesis, does not result in a higher incidence of congeni-
tal malformations.4,6-9,23
Two children born 10 days after high-dose chemotherapy for
acute lymphatic leukemia developed a neutro/pancytopenia. Neona-
tal bone marrow insufficiency after prenatal chemotherapy exposure
was described previously.4,24 The hematologic toxicity in the two
children suggests that a considerable fraction of these drugs passes
through the placenta. In literature on cancer treatment during
pregnancy, growth restriction is a permanent concern4,24,25 which
is confirmed by the findings in this study. The largest proportion of
small-for-gestational-age children was seen in patients with hemato-
logic tumors.
Ring et al6 described a series of pregnant women with breast
cancer treated with chemotherapy during pregnancy. Data on birth
weight were available in 17 children, and they were all above the 10th
percentile for gestational age. Also in this study, the birth weight in
breast cancer patients receiving chemotherapy in pregnancy was
within normal ranges (4 of 34 children had a birth weight below 10th
percentile of gestational age). Since small-for-gestational-age children
were observed only in mothers with certain tumor types such as
hematologic tumors but not in mothers with breast cancer, the data
suggest that an impact on fetal growth might be related to specific
cancer types and treatments. Whether the effect is determined by the
maternal illness that is associated with malnutrition and a catabolic
status,26 or by direct or indirect effects of the treatment remains an
unanswered question.
Patients receiving chemotherapy had an increased risk of pre-
term labor. However, the time interval between the administration
of chemotherapy and the onset of contractions varied substan-
tially. The underlying mechanism is unclear. Physical or psycholog-
ical stress can inducepreterm labor throughactivationof thematernal
hypothalamic-pituitary-adrenal axis;27-29 thus, the stress associated
with cancer diagnosis and treatment may contribute. Alternatively,
fetal stress or uteroplacental vasculopathy may activate the fetal
hypothalamic-pituitary-adrenal axis and induce labor.30 The poten-
tial role of chemotherapy in preterm labor needs additional investiga-
tion.Apoptosis in amnion epithelial and chorion trophoblast layers of
fetal membranes is known as an important factor in the pathogenesis
ofmembrane rupturing.31,32 This process theoreticallymight be facil-
itated by exposure to chemotherapy.
It is accepted that interruption of pregnancy is indicated in in-
stances of a poor maternal prognosis or when there is an urgent need
for cytotoxic treatment in the first trimester.4,13,25 In this study, the
main indication (in29of 30patients) forpregnancy terminationwas a
maternal malignancy. Seventeen of these pregnancies were diag-
nosed in the first trimester. Of the 13 pregnancies that were ended
thereafter, eight had a poor maternal prognosis at diagnosis. One
patienthada stage IB1 cervical cancerdiagnosedat 15weeks forwhich
therapy during pregnancy is still considered experimental. In four
patients, the pregnancy was terminated because of the need for onco-
logic treatment while, according to current knowledge, this wasmed-
ically not strictly indicated. Surgical andmedical treatment for breast
cancer (n 3; T1-2 at 19, 20, and 22 weeks) and Hodgkin’s disease
(n 1; 20 weeks) is possible during pregnancy. The fact that three of
these four instances of pregnancy termination were treated in the
same city emphasizes the need for sufficient information and edu-
cation on this topic.
The most frequently encountered tumor types were breast can-
cer, hematologic malignancies, skin cancer, and cervical cancer. The
frequencies follow thedistributionof cancer in the general population
in this age group (20 to40years) in this area.33Other studies oncancer
during pregnancy described proportionally more cervical cancers
(maximum of 15%), malignant melanomas (maximum of 31%), or
thyroid cancer.11,13,34 Differences in inclusion criteria and regional
differences in incidence, sensitization campaigns, and screening pro-
grams might explain the difference between our study and others.
Because tumor distribution is comparable to that in the nonpregnant
populationof that age group,we can conclude that the concurrenceof
cancer and pregnancymost likely reflects the patients’s age (mean age
of 33 years).
An important strength of this study is that a large series of only
invasive cancersdiagnosedduringpregnancywas included (excluding
preinvasive and postpartumdiagnoses). Furthermore, the interpreta-
tion of the birth weight was adjusted for gestational age and sex.
Limitations to our study include the absence of centralized national
registries for the entity “cancer and pregnancy.” Second, there is no
separate registration for termination of pregnancy in most hospitals.
Therefore, we can assume an under-registration of the early pregnan-
cies that miscarried or were interrupted.
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The findings of this study show an overall good outcome of
pregnancies complicatedwith cancer.However, ahigh rateofpreterm
labor inductionwith a subsequent high rate of admission of infants to
the NICU was observed. Interdisciplinary decision making on the
timing of delivery by obstetricians and neonatologists is necessary.
Preferably, delivery should not be induced before 35 to 37 weeks.
Current data confirm that cytotoxic treatment administered during
the secondand third trimestersofpregnancydoesnot increase the rate
of congenital malformations.
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